Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06910124 · ClinicalTrials.gov registry record · Phase 2

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

A Phase 2 study of Multiple Myeloma, sponsored by Dickran Kazandjian, MD.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
1
Study location

NCT06910124: Recruiting Phase 2 study of Multiple Myeloma, sponsored by Dickran Kazandjian, MD.

NCT06910124 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Dickran Kazandjian, MD. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06910124, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Dickran Kazandjian, MD.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) status. For participants that start the study with residual multiple myeloma cells in participants' bodies: to determine how long you remain MRD-. 2. Increase the length of time that participants' disease is controlled. For participants with relapsed disease, to determine whether participants can re-attain MRD- status. 3. Increase the length of time that participants' disease responds to treatment. The researchers also want to find out the effects that linvoseltamab has on participants and participants' condition.

Primary Outcome

The number of patients who experience MRD negativity (10\^-5 sensitivity by 12 cycles of linvoseltamab (MRD conversion rate) will be determined by dividing this number of MRD negative responses by the total number of evaluable patients. MRD negativity rate (\<10\^-5) by 12 cycles of linvoseltamab

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Lenalidomide
  • BIOLOGICAL Linvoseltamab

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-12-02
Est. Completion 2032-12-02
Phase Phase 2
Dickran Kazandjian, MD

2 total trials

What NCT06910124 shows while recruiting

NCT06910124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.

NCT06910124 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06910124 about?

NCT06910124 is a clinical study titled "Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse". The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) stat...

What is the current status of trial NCT06910124?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-02. Estimated completion is 2032-12-02.

What conditions does trial NCT06910124 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06910124?

The interventions under investigation include: Lenalidomide (DRUG), Linvoseltamab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06910124?

This trial is sponsored by Dickran Kazandjian, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06910124 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06910124's enrollment target sits among peer trials

32 324th of 438 higher than 104 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06910124

Source: ClinicalTrials.gov NCT06910124, the US trial registry maintained by the National Library of Medicine. NCT06910124 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.